Investigational Drug Information for MK-6482
✉ Email this page to a colleague
What is the drug development status for MK-6482?
MK-6482 is an investigational drug.
There have been 20 clinical trials for MK-6482.
The most recent clinical trial was a Phase 1 trial, which was initiated on March 15th 2022.
The most common disease conditions in clinical trials are Carcinoma, Renal Cell, Carcinoma, and Kidney Neoplasms. The leading clinical trial sponsors are Merck Sharp & Dohme Corp., Peloton Therapeutics, Inc., and Eisai Inc.
There are five US patents protecting this investigational drug and fifty-six international patents.
Summary for MK-6482
US Patents | 5 |
International Patents | 56 |
US Patent Applications | 33 |
WIPO Patent Applications | 11 |
Japanese Patent Applications | 4 |
Clinical Trial Progress | Phase 1 (2022-03-15) |
Vendors | 35 |
Recent Clinical Trials for MK-6482
Title | Sponsor | Phase |
---|---|---|
A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024) | Merck Sharp & Dohme LLC | Phase 1/Phase 2 |
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal | Eisai Inc. | Phase 3 |
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal | Merck Sharp & Dohme LLC | Phase 3 |
Clinical Trial Summary for MK-6482
Top disease conditions for MK-6482
Top clinical trial sponsors for MK-6482
US Patents for MK-6482
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
MK-6482 | ⤷ Sign Up | Compositions for use in treating pulmonary arterial hypertension | Peloton Therapeutics, Inc. (Dallas, TX) | ⤷ Sign Up |
MK-6482 | ⤷ Sign Up | Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof | PELOTON THERAPEUTICS, INC. (Dallas, TX) | ⤷ Sign Up |
MK-6482 | ⤷ Sign Up | Combination therapy of a HIF-2-.alpha. inhibitor and an immunotherapeutic agent and uses thereof | Peloton Therapeutics, Inc. (Dallas, TX) | ⤷ Sign Up |
MK-6482 | ⤷ Sign Up | Aryl ethers and uses thereof | PELOTON THERAPEUTICS, INC. (Dallas, TX) | ⤷ Sign Up |
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for MK-6482
Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
---|---|---|---|---|
MK-6482 | European Patent Office | EP3203991 | 2034-10-10 | ⤷ Sign Up |
MK-6482 | World Intellectual Property Organization (WIPO) | WO2016057242 | 2034-10-10 | ⤷ Sign Up |
MK-6482 | Argentina | AR097600 | 2033-09-09 | ⤷ Sign Up |
MK-6482 | Australia | AU2014318025 | 2033-09-09 | ⤷ Sign Up |
>Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |